文献速递肿瘤 PET/CT

混合68Ga-PSMA配体PET/CT在根据Phoenix标准定义的前列腺癌根治性放疗后生化复发患者中的检测效能

Detection Efficacy of Hybrid 68Ga-PSMA Ligand PET/CT in Prostate Cancer Patients with Biochemical Recurrence After Primary Radiation Therapy Defined by Phoenix Criteria.
PubMed 文献 · J Nucl Med · 2017-02-16

这项回顾性研究评估了68Ga-PSMA配体PET/CT在118例根据Phoenix标准定义的前列腺癌生化复发患者中的检测率,这些患者此前接受过外照射放疗或近距离放疗。总体检测率为90.7%,且检测率随PSA升高而升高(PSA 2至<5、5至<10、≥10 ng/mL分别为81.8%、95.3%、96.8%,P=0.0377),接受雄激素剥夺治疗(ADT)者检测率更高(97.7% vs 86.3%,P=0.0381)。

要点

  • 118例放疗后生化复发患者中,68Ga-PSMA配体PET/CT总体检测率为90.7%(107/118)。
  • 检测率随PSA升高而升高:PSA 2至<5、5至<10、≥10 ng/mL分别为81.8%、95.3%、96.8%(P=0.0377)。
  • ADT组检测率97.7%高于无ADT组86.3%(P=0.0381),与Gleason评分无关。

核心结论

  • 68Ga-PSMA配体PET/CT在根治性放疗后生化复发的前列腺癌患者中显示出高检测率。
  • 检测率与PSA升高及同期ADT正相关。
  • 该检查可区分局部复发与转移性疾病,可能对后续临床管理有重要影响。

研究设计与样本

  • 回顾性研究,最终纳入118例根据Phoenix标准定义的外照射放疗或近距离放疗后生化复发的前列腺癌患者。
  • 患者中位PSA为6.4 ng/mL(范围2.2-158.4 ng/mL;四分位距4.2-10.2 ng/mL)。
  • 77例接受外照射放疗,41例接受近距离放疗;45例在PET/CT前至少6个月内接受ADT。

主要发现

  • 107/118例(90.7%)在68Ga-PSMA配体PET/CT上显示提示肿瘤复发的病理学表现。
  • PSA 2至<5、5至<10、≥10 ng/mL的检测率分别为81.8%(36/44)、95.3%(41/43)、96.8%(30/31),P=0.0377。
  • 107例阳性患者中,68例(63.5%)提示局部复发,64例(59.8%)提示远处病灶,25例(23.4%)同时提示局部复发和远处病灶。
  • ADT组检测率97.7%高于无ADT组86.3%(P=0.0381);原发Gleason评分≥8组92.0%与≤7组90.2%无显著差异(P=0.6346)。
  • SUVmax与PSA和ADT显著相关(P=0.018和0.004),SUVmean与PSA和ADT显著相关(P=0.025和0.007)。

临床怎么用

  • 作者认为68Ga-PSMA配体PET/CT可区分局部复发与转移性疾病,可能对后续临床管理有重要影响。

局限性

  • 主要局限性是大多数患者缺乏组织病理学证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aim of this retrospective study was to evaluate the detection rate of Glu-NH-CO-NH-Lys-(Ahx)-[68Ga(HBED-CC)] (68Ga-PSMA ligand; PSMA is prostate-specific membrane antigen) PET/CT in patients with biochemical recurrent prostate cancer defined by Phoenix criteria after external-beam radiotherapy or brachytherapy as primary treatment. Methods: One hundred eighteen patients with a median prostate-specific antigen (PSA) of 6.4 ng/mL (range, 2.2-158.4 ng/mL; interquartile range, 4.2-10.2 ng/mL) were finally eligible for this retrospective analysis. Seventy-seven and 41 patients had been treated by external-beam radiotherapy or brachytherapy, respectively. Of the 118 patients, 45 were receiving androgen-deprivation therapy (ADT) within at least 6 mo before the PET/CT. The detection rates were stratified by PSA. The influence of primary Gleason score and ADT was assessed. Relationships between SUV and clinical as well as pathologic features in patients with positive findings were analyzed using univariate and multivariable linear regression models. Results: One hundred seven of 118 patients (90.7%) showed pathologic findings indicative for tumor recurrence in 68Ga-PSMA ligand PET/CT. The detection rates were 81.8% (36/44), 95.3% (41/43), and 96.8% (30/31) for PSA of 2 to <5, 5 to <10, and ≥10 ng/mL, respectively (P = 0.0377). 68Ga-PSMA ligand PET/CT indicated local recurrence in 68 of 107 patients (63.5%), distant lesions in 64 of 107 patients (59.8%), and local recurrence as well as distant lesions in 25 of 107 patients (23.4%). The detection rate was significantly higher in patients with ADT (97.7%) versus without ADT (86.3%, P = 0.0381), but independent from primary Gleason score ≥ 8 (92.0%) versus ≤ 7 (90.2%, P = 0.6346). SUVmax and SUVmean were significantly associated with PSA and ADT (P = 0.018 and 0.004 for SUVmax, respectively; P = 0.025 and 0.007 for SUVmean, respectively). Conclusion:68Ga-PSMA ligand PET/CT demonstrates high detection rates in patients with biochemical recurrence of prostate cancer after primary radiation therapy. The detection rate was positively associated to increasing PSA as well as concomitant ADT. 68Ga-PSMA ligand PET/CT enables discrimination of local versus metastatic disease and thus might have a crucial impact on further clinical management. A major limitation of this study is the lack of histopathologic proof in most patients.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Einspieler I, Rauscher I, Düwel C, et al. Detection Efficacy of Hybrid 68Ga-PSMA Ligand PET/CT in Prostate Cancer Patients with Biochemical Recurrence After Primary Radiation Therapy Defined by Phoenix Criteria. J Nucl Med. 2017. PMID: 28209912. doi:10.2967/jnumed.116.184457

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。